Elixir Medical Corporation to Announce Six-Month Results of the DESolve Fully Bioresorbable Coronary Scaffold System Pivotal Trial at Late Breaking Trial Session of EuroPCR

Wed, 05/01/2013 - 7:00am
The Associated Press

SUNNYVALE, Calif.--(BUSINESS WIRE)--May 1, 2013--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it will release six-month pivotal, clinical trial results for its fully bioresorbable drug-eluting scaffold system, the DESolve ® Bioresorbable Coronary Scaffold, at the EuroPCR session of “From Late Breaking Trial to Clinical Practice” in Paris on Tues., May 21 st 2013, in the Main Arena of the conference. EuroPCR is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions.

The multi-center, prospective DESolve Nx Trial was designed to enroll 120 patients at 15 centers in Germany, Belgium, Poland, Brazil and New Zealand. The primary safety endpoint of the DESolve Nx trial is the composite of major adverse cardiac events (MACE) comprised of cardiac death, target vessel myocardial infarction (MI) and clinically-indicated target vessel revascularization (TLR). The primary angiographic endpoint of the trial is in-scaffold late lumen loss at 6 months as assessed by QCA (quantitative coronary angiography). In a sub-set of patients, additional QCA assessment will be conducted at 24 months; scaffold and vessel assessment using IVUS (Intravascular Ultrasound), OCT (Optical Coherent Tomography) were to be conducted at baseline, 6 and 24 months; and MSCT (Multi Slice Computed Tomography) at 12 months thus providing long-term assessment of the scaffold and surrounding vessel.

Elixir will also announce additional new data on its fully bioresorbable scaffold and other drug eluting stent platforms during the conference. Following are some of the highlights of Elixir Medical’s programs and activities at the EuroPCR conference (in chronological order) at the Palais Des Congres de Paris in Central European Summer Time (CEST): Elixir Medical will also have 5 poster presentations in the Poster Area and the Moderated Poster Area on Wed., May 22.

Elixir Medical will have a booth at EuroPCR: Booth # F5, Second Floor. The booth will be open Tues., May 21 through Fri., May 24.

About Elixir Medical
Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.